Влияние антицитокиновой терапии на течение атеросклероза у лиц с ранними проявлениями недостаточности мозгового кровообращения

Список литературы

1. Белова Л.А. Биохимия процессов воспаления и поражения сосудов. Роль нейтрофилов. //Биохимия.-1997.-Т.62(6).-С.659−668.
2. Гусев Е.И., Боголепов Н. Н., Бурд Г. С. Сосудистые заболевания головного мозга.- М.: 1974.
3. Демографический ежегодник России. 2008.- М.: Росстат, 2008.
4. Климов А.Н., Никульчева Н. Г. Обмен липидов и липопротеидов и его нарушения.- Спб.: Питер Ком, 1999.
5. Серов В.В., Пауков B.C. Воспаление. Руководство для врачей.- М.: Медицина, 1995.
6. Шмидт Е.В. Стеноз и тромбоз сонных артерий и нарушения мозгового кровообращения.- М.: 1963.
7. Ярилин А.А. Основы иммунологии.- М.: Медицина, 1999.
8. Sobenin I.A., Suprun I.V., Orekhov A.N. (Собенин И.А., Супрун И. В., Орехов А.Н.) New insight into non-statin prevention and treatment of atherosclerosis, in Atherosclerosis: risk factors, diagnosis, and treatment. // Monduzzi Editore.-2002.-P.305−308.
9. Achenbach S., Daniel W.G. Computed tomography of the coronary arteries: more than meets the (angiographic) eye. // J. Am. Coll. Cardiol.-2005.-V.46.-P. 155−7.
10. Aidinian G., Weiswasser J.M., Arora S., Abularrage C.J., Singh N., Sidawy A.N. Carotid Plaque Morphologic Characteristics. // Persp. Vase. Surg. Endovasc. Ther.-2006.-V. 18(l).-P.63−70.
11. Akihisa Т., Yasukawa K., Oinuma H., Kasahara Y., Yamanouchi S., Takido M., Kumaki K., Tamura Т. Triterpene alcohols from the flowers of compositae and their anti-inflammatory effects. // Phytochemistry.-1996.-V.43(6).-P.1255−60.
12. Asres K., Seyoum A., Veeresham C., Bucar F., Gibbons S. Naturally derived anti-HIV agents. // Phytother Res.-2005.-V.19.-P.557−81.
13. Baldassarre D., Amato M., Bondioli A., Sirtori C.R., Tremoli E. Carotid Artery Intima-Media Thickness Measured by Ultrasonography in Normal Clinical Practice Correlates Well With Atherosclerosis Risk Factors. // Stroke.-2000.-V.31.-P.2426−30.
14. Banati R.B., Gehrmann J., Schubert P., Kreutzberg G.W. Cytotoxicity of microglia. // Glia.-1993.-V.7.-P.l 11−8.
15. Bani S., Gautam M., Sheikh F.A., Khan B., Satti N.K., Suri K.A. et al. Selective Thl up-regulating activity of Withania somnifera aqueous extract in an experimental system using flow cytometry. // J Ethnopharmacol.-2006.-V.107.-P.107−15.
16. Barak V., Halperin T., Kalickman I. The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines. // Eur Cytokine Netw.-2001.-V.12(2).-P.290−6.
17. Barath P., Fishbein M., Cao J., Berenson J., Helfant R., Forrester J. Detection and localization of tumour necrosis factor in human atheroma. // Am J Pathol.-1990.-V.65.-P.297−302.
18. Barone F.C., Arvin B., White R.F., Miller A., Webb C.L., Willette R.N., Lysko P.G., Feuerstein G.Z. Tumor necrosis factor-a: a mediator of focal ischemic brain injury. // Stroke.-1997.-V.28.-P. 1233−44.
19. Bedirli A., Salman B., Pasaoglu H., Ofluoglu E., Sakrak O. Effects of Nuclear Factor-kappaB Inhibitors on Colon Anastomotic Healing in Rats. // J Surg Res.-2010.-Feb, l l (Epub ahead of print).
20. Beneviste E.N. Cytokines: influence on glial cell gene expression and function. // Neuroimmunoendocrinology.-1992.-V.52.-P. 106−53.
21. Bermel R.A., Rudick R.A. Interferon-b treatment for multiple sclerosis. // Neurotherapeutics.-2007.-V.4.-P.633−46.
22. Betz K., Schielke G. P, Yang, G. Interleukin 1 in cerebral ischaemia. // Keio Journal of Medicine.-1996.-V.45.-P.230−8.
23. Beutler B., Cerami A. The biology of cachectin TNF-a: a primary mediator of the host response. // Annual Review of Immunology.-1989.-V.7.-P.625
24. Bevilacqua M.P., Pober J.S., Majeau G.R., Cotran R.S., Gimbrone M.A. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. // J Exp Med.- 1984.-V.160.-P.618−23.
25. Biasucci L.M., Vitelli A., Liuzzo G., Altamura S., Caliguri G., Monaco C., Rebuzzi A.G., Ciliberto G., Maseri A. Elevated levels of interleukin-6 in unstable angina. // Circulation.-1996.-V.94.-P.874−7.
26. Blankenhorn D. H., Selzer R.H., Crawford D.W., Barth J.D., Liu C.R., Liu C.H., Mack W.J., Alaupovic P. Beneficial effects of colestipol-niacin therapy on the common carotid artery. // Circulation.-1993.-V.88.-P.20−8.
27. Bogdan C., Vodovotz Y., Paik J., Xie Q., Nathan C. Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. // J Leukoc Biol.-1994.-V.55.-P.227−33.
28. Bonita R. Epidemiology of stroke. // Lancet.-1992.-V.339(8789).-P.342
29. Bots M.L., Hoes A.W., Koudstaal P.J., et al. Common carotid intimamedia thickness and risk of stroke and myocardial infarction: The Rotterdam Study. // Circulation.-1997.-V.96.-P.1432−7.
30. Bots M.L., van Swieten J.C., Breteler M.M.B., de Jong P.T., van Gijn J., Hofinan A., Grobbee D.E. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. //Lancet.-1993.-V.341.-P. 1232−7.
31. Brown B.G., Zhao X.Q., Sacco D.I., Albers J.J. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. // Circulation.-1993-.V.87.-P. 1781−91.
32. Bruce A.J., Boling W., Kindy M.S., Peshon J., Kraemer P.J., Carpenter M.K., Holtsberg F.W., Mattson M.P. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. // Nat Med.-1996.-V.2.-P.788−94.
33. Burke A.P., Farb A., Malcom G.T., Liang Y.H., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronaiy disease who died suddenly. //N. Engl. J. Med.-1997.-V.336.-P. 1276−82.
34. Calabro P., Willerson J.T., Yeh E.T. Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells. // Circulation.-2003.-V. 108.-P. 1930−2.
35. Chambless L.E., Folsom A.R., Clegg L.X. Carotid wall thickness is predictive of incident clinical stroke: The Atherosclerosis Risk in Communities (ARIC) Study. // Am J Epidemiol.-2000.-V. 151 .-P.478−87.
36. Chambless L.E., Folsom A.R., Davis V., Sharrett R., Heiss G., Sorlie P., Szklo M., Howard G., Evans G.W. Risk Factors for Progression of Common Carotid Atherosclerosis: The Atherosclerosis Risk in Communities Study, 1987−1998. // Am
37. JEpidemiol.-2002.-V.155.-P.38−47.
38. Chambers B.R., Norris J.W. Outcome in patients with asymptomatic neck bruits. //N. Engl. J. Med.-1986.-V.315.-P.860−5.
39. Cheng A.C., Stephens D.P., Cunie B.J. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adluts. // Cochrane Database Syst Rev.-2007.-V.2.-CD004400.
40. Chomarat P., Banchereau J., Davoust J., Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. // Nat Immunol.-2006.-V. 1 .-P.510−4.
41. Chuaqui R., Tapia J. Histologic assessment of the age of recent brain infarcts in man. // J Neuropathol Exp Neurol.-1993.-V.52.-P.481−9.
42. Chung K.F., Barnes P.J. Cytokines in asthma. // Thorax.-1999.-V.54.-P.825−57.
43. Condie R.C., Herring A., Koh W.S., Lee M., Kaminski N.E. Cannabinoid inhibition of adenylate-mediated signal transduction and IL-2 expression in the murine T-cell line, EL4. IL-2. // J Biol Chem.-1996.-V.271.-P.13 175−83.
44. Cooksley W.G., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T. et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. // J Viral Hepat.-2003.-V.10.-P.298−305.
45. Cowan M.M. Plant products as antimicrobial agents. // Clin Microbiol
46. Rev.-1999.-V.12.-P.564−82.
47. Crooke S.T. Oligonucleotide-based drugs in the control of cytokine synthesis in Novel Cytokine Inhibitors. // Birkhauser Verlag A.G.-2000,83−101.
48. Crouse J.R. III. Imaging atherosclerosis: state of the art. // J. Lipid Res.-2006.-V.47.-P. 1677−99.
49. Crouse J.R., Byington R.P., Bond M.G., Espeland M.A., Craven T.E., Sprinkle J.W., McGovern M.E., Furberg C.D. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). // Am. J. Cardiol.-1995.-V.75.-P.455−9.
50. Cybulsky M.I., Iiyama K., Li H., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. // J Clin Invest.-2001.-V.107.-P. 1255−62.
51. Danese S., Semeraro S., Armuzzi A., Papa A., Gasbarrini A. Biological therapies for inflammatory bowel disease: research drives clinics. // Mini Rev Med Chem.2006.-V.6.-P.771−84.
52. Daugherty A., Webb N.R., Rateri D.L., King V.L. The Immune System and Atherogenesis. Cytokine regulation of macrophage functions in atherogenesis. // J. Lipid Res.-2005.-V.46.-P. 1812−22.
53. Davies M.J., Gordon J.L., Gearing A.J., Pigott R., Woolf N., Katz D., Kyriakopoulos A. The expression of adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. // J Pathol.-1993 .-V.l 71.-P.223−9.
54. Davignon J. Beneficial Cardiovascular Pleiotropic Effects of Statins. // Circulation.-2004.-V. 109.-P.39−43.
55. Dinarello C.A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. // N Engl J Med.-2000.-V.-343.-P.732−4.
56. Dinarello C.A. Blocking IL-1 in systemic inflammation. // J Exp Med.-2005 .-V.201.-P. 1355−9.
57. Diwanay S., Chitre D., Patwardhan B. Immunoprotection by botanical drugs in cancer chemotherapy. // J Ethnopharmacol.-2004.-V.90.-P.49−55.
58. Doan T., Massarotti E. Rheumatoid Arthritis: An overview of new and emerging therapies. // J. Clin. Pharmacol.-2005.-V.45.-P.751−62.
59. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. // Oncology (Williston Park).-2002.-V. 16(13).-P.4—10.
60. El-Obeid A., Al-Harbi S., Al-Jomah N., Hassib A. Herbal melanin modulates tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) production. // Phytomedicine.-2006.-V.13.-P.324−33.
61. Entman M.L., Smith W.C. Postreperfiision inflammation: a model for reaction to injury in cardiovascular disease. // Cardiovasc. Res.-1994.-V.28.-P.1301−11.
62. Falk E. Pathogenesis of Atherosclerosis. // J Am Coll Cardiol.-2006.-V.47.-P.7−12.
63. Farb A., Burke A.P., Tang A.L., Liang T.Y., Mannan P., Smialek J.,
64. Virmani R. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronaiy death. // Circulation.-1996.-V.93.-P.1354−63.
65. Fetterman J.W., Zdanowicz M.M. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. // Am J Health Syst Pharm.-2009.-V.66(13).-P. 1169−79.
66. Feuerstein G.Z., Liu T., Barone F.C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-a. // Cerebrovasc Brain Metab Rev.-1994.-V.6.-P.341−60.
67. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. // Ann NY Acad Sci,-1995.-V.748.-P.501−7.
68. Garcia J.H., Liu K.F., Ho K.L. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. // Stroke.-1995 .-V.26.-P.636−43.
69. Garcia J.H., Liu K.F. Relton J.K. Interleukin 1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. // American Journal of Pathology.-1995.-V.147.-P. 1477−86.
70. Garcia J.H., Yoshida Y., Chen H., Li Y., Zhang Z.G., Lian J., Chen S., Chopp M. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. // Am J Pathol.-1993.-V. 142.-623−35.
71. Genovese M.C. Biologic therapic in clinical development for the treatment of rheumatoid arthritis. I IJ Clin Rheumatol.-V.2005.-P.l 1(3):S45-S54.
72. Geroulakos G.O., Gorman D.J., Kalodiki E., Sheridan D.J., Nicolaides A.N. The carotid intima-media thickness as a marker of the presence ofsevere symptomatic coronary artery disease. // Eur. Heart J.- 1994.-V.15.-P.781−5.
73. Giulian D., Vaca K., Corpuz M. Brain glia release factors with opposing actions upon neuronal survival. // Journal of Neuroscience.-1992.-V.13.-P.29−37.
74. Gullo V.P., McAlpine J., Lam K., Baker D., Petersen F. Drug discovery from natural products. // J Ind Microbiol Biotechnol.-2006.-V.33.-P.523−31.
75. Gussekloo J., Schaap M.C., Frolich M., Blauw G.J., Westendorp R.G. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. // Arterioscler Thromb Vase Biol.-2000.-V.20.-P. 1047−51.
76. Harokopakis E., Albzreh M.H., Haase E.M., Scannapieco F.A., Hajishengallis G. J. Inhibition of proinflammatory activities of major periodontal pathogens by aqueous extracts from elder flower (Sambucus nigra). // Periodontol.-2006.-V.77(2).-P.271−9.
77. Herath K.B., Jayasuriya H., Ondeyka J.G., Polishook J.D., Bills G.F., Dombrowski A.W. et al. Isolation and structures of novel fungal metabolites as chemokine receptor (CCR2) antagonists. // J Antibiot (Tokyo).~2005.-V.58.-P.686−94.
78. Higa S., Hirano T., Kotani M., Matsumoto M., Fujita A., Suemura M. et al. Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. // J Allergy Clin Immunol.-2003.-V.l 11.-P. 1299−306.
79. Hong J.H., Yu E.S., Han A.-R., Nam J.-W., Seo E.K., Hwang E.S. Isoleutherin and eleutherinol, naturally occuring selective modulators of Th cellmediated immune responses. // Biochem Biophys Res Commun.-2008.-V.371.-P.278−82.
80. Hopkins S.J., Rothwell N.J. Cytokines in the nervous system I: Expression and recognition. // Trends in Neurosciences.-1995.-V.18.-P.83−8.
81. Horrigan L.A., Kelly J.P., Connor T.J. Immunomodulatory effects of caffeine: friend or foe? // Pharmacol Ther.-2006.-V. 111 .-P.877−92.
82. Hu S., Sheng W.S., Peterson P.K., Chao C.C. Cytokine modulation of murine microglial cell superoxide production. // Glia.-1995.-V.13.-P.45−50.
83. Huang S., Mills L., Mian B., Tellez C" McCarty M., Yang X.D. et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibitangiogenesis, tumor growth, and metastasis of human melanoma. // Am J Pathol.-2002.-V. 161 .-P.125−34.
84. Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. // Arterioscler Thromb Vase Biol.-1999.-V.19.-P.2364−7.
85. Johnsen S.H., Mathiesen E.B. Carotid plaque compared with intima-media thickness as a predictor of coronary and cerebrovascular disease. // Curr Cardiol Rep.-2009.-V.ll (l).-P.21−7.
86. Jovinge S., Hamsten A., Tornvall P. et al. Evidence for a role of tumor necrosis factor-a in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. // Metabolism.-1998.-V.47.-P.113−8.
87. Kaski J.C., Zouridakis E.G. Inflammation, infection and acute coronary plaque events. // Eur. Heart J.-2001.-V.3-P.10−15.
88. Katiyar S.K. UV-induced immune suppression and photocarcinogenesis: chemoprevention by dietary botanical agents. // Cancer.-2007.-L.255.-P. 1−11.
89. Kishimoto T., Akira S., Narazaki M. et al. IL-6 family of cytokinesand gpll30. // BIood.-1995.-V.86.-P. 1243−54.
90. Kochanek P.M., Hallenbeck J.M. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. // Stroke.-1992.-V.23.-P.-1367−79.
91. Kodama M., Yamasaki Y., Sakamoto K., Yoshioka R., Matshuisa M., Kajimoto Y., Kosugi K., Ueda N., Hori M. Antiplatelet drugs attenuate progression of carotid intimamedia thickness in subjects with type 2 diabetes. // Thromb. Res.2000.-V.97.-P.239−45.
92. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O’Connor B.J., Walls C.M. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. // Lancet.-2000.-V.356.-P.2144−8.
93. Libby P. Inflammation and cardiovascular disease mechanisms. // Am. J. Clin. Nutr.-2006.-V.83(2).-P.456S-60S.
94. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. // Circulation.-2002.-V. 105.-P. 1135−43.
95. Lim T.K., Lim E., Dwivedi G., Kooner J., Senior R. Normal value of carotid intima-media thickness—a surrogate marker of atherosclerosis: quantitative assessment by B-mode carotid ultrasound. // J Am Soc Echocardiogr.-2008.-V.21(2).-P. 112−6.
96. Lind L. Circulating markers of inflammation and atherosclerosis. // Atherosclerosis.-2003 .-V. 169.-P.203−14.
97. Lit L.C., Wong C.K., Li E.K., Tarn L.S., Lam C.W., Lo Y.M. Elevated gene expression of Thl/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. // J Rheumatol.-2007.-V.34.-P.89−96.
98. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis. // Circulation.-2007.-V.l 15.-P.459−67.
99. Lu H., Ouyang W., Huang C. Inflammation, a key event in cancer development. //Mol. CancerRes.-2006.-V.4.-P.221−33.
100. Mach F., Schonbeck U., Sukhova G.K., Atkinson E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. // Nature.-1998.-V.394,1. Р.200−3.
101. Mallat Z., Besnard S., Duriez M. et al. Protective role of interleukin-10 in atherosclerosis. //Circ. Res.-1999.-V.85.-P.17−24.
102. Mangge H., Hubmann H., Pilz S., Schauenstein K., Renner W., Marz W. Beyond cholesterol-inflammatory cytokines, the key mediators in atherosclerosis. // Clin Chem Lab Med.-2004.-V.42.-P.467−74.
103. Manolio T.A., Kronmal R.A., Burke G.L., O’Leary D.H., Price T.R. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. // Stroke.-1996.-V.27.-P. 1479−86.
104. Manolio T.A., Kronmal R.A., Burke G.L., Poirier V., O’Leary D.H., Gardin J.M., Fried L.P., Steinberg E.P., Bryan R.N. Magnetic resonance abnormalities and cardiovascular disease in older adults. // Stroke.-1994.-V.25.-P.318−27.
105. Marciano B.E., Wesley R., De Carlo E.S., Anderson V.L., Barnhart L.A., Darnell D. et al. Long-term interferon-g therapy for patients with chronic granulomatous disease. // Clin Infect Dis.-2004.-V.39.-P.692−9.
106. Marshall J.K. Ilodecakin. // Schering-Plough Corp. Idrugs.-1999.-V.2.-P. 1045−58.
107. Maseri A., Cianflone D. Inflammation in acute coronary syndromes. // Eur. Heart J.-2002.-V.4.-P.8−13.
108. Matsumoto K., Sera Y., Abe Y., Tominaga Т., Yeki Y., Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. // Diabetes Res. Clin. Pract.-2004.-V.64.-P.225−8.
109. McCarron R.M., Wang L., Siren A.L., Spatz M., Hallenbeck J.M. Adhesion molecules on normotensive and hypertensive rat brain endothelial cells. // Proc Soc Exp Biol Med.-1994.-V.205.-P.257−62.
110. McClelland R.L., Chung H., Detrano R., Post W., Kronmal R.A. Distribution of coronaiy artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). // Circulation.-2006.-V.113.-P.30−7.
111. McMahon S., Sharpe N., Gamble G., Clague A., Mhurchu C.N., Clark
112. Mohagheghpour N., Waleh N., Garger S.J., Dousman L., Grill L.K., Tuse D. Synthetic melanin suppresses production of proinflammatory cytokines. // Cell Immunol.-2000.-V.199.-P, 25−36.
113. Moon H.I., Chung J.H., Lee J.K., Zee O.P. Triterpenoid saponin from Viola hondoensis W. Becker et H Boss, and their effect on MMP-1 and type I procollagen expression. //Arch Pharm Res.-2004.-V.27(7).-P.730−3.
114. Moore K.W., O’Garra A., de Waal Malefyt R. et al. Interleukin-10. // Annu. Rev. Immunology.-1993.-V. 11.-P. 165−90.
115. Moyer C.F., Sajuthi D., Tulli H., Williams J.K. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. // Amer. J. Pathology.-1991.-V.138.-P.951−60.
116. Muir K.W., Tyrrell P., Sattar N., Warburton E. Inflammation and ischaemic stroke. // Curr OpinNeurol.-2007.-20(3).-P.334−42.
117. Nakashima Y., Raines E.W., Plump A.S., Breslow J.L., Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. // Arterioscler Thromb Vase Biol.-1998.-V.18.-P.842−51.
118. Nawashiro H., Martin D., Hallenbeck J.M. Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. // J Cereb Blood Flow Metab.-1997.-V.17.-P.229−32.
119. Nawashiro H., Tasaki K., Ruetzler C.A., Hallenbeck J.M. TNF-a pretreatment induces protective effects against focal cerebral ischemia in mice. // J Cereb Blood Flow Metab.-1997.-V.17.-P.483−90.
120. Neyer J. A report from American Heart Association Statistics Committee and Stroke Statistics Subcommittee. II Circulation.-2007-.V. 115.-P.69−171.
121. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyokardial infarction remodeling. // Circ. Res.-2004.-V.94.-P. 1543−53.
122. Niiro H., Otsuka T., Kuga S., Nemoto Y., Abe M., Hara N., Nakano T., Ogo T., Niho Y. IL-10 inhibits prostaglandin E2 production by lipopolysaccharidestimulated monocytes. // Int Immunol.-1994.-V.6.-P.661−4.
123. Odell P.M., Anderson K.M., Kannel W.B. New models for predicting cardiovascular events. // J Clin Epidemiol.-1994.-V.47(6).-P.583−92.
124. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell.-1990.-V.62.-P.3−6.
125. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. // Lancet.-1987.-V.1.-P.893−5.
126. Pantoni L., C. Sarti, D. Inzitari. Cytokines and Cell Adhesion Molecules in Cerebral Ischemia: Experimental Bases and Therapeutic Perspectives. // Arterioscler Thromb Vase Biol.-1998.-V.18.-P.503−13.
127. Paoletti R., Gotto A.M., Hajjar D.P. Inflammation in Atherosclerosis and Implications for Therapy. // Circulation.-2004.-V.109.-P.20−26.
128. Paul A.T., Gohil V.M., Bhutani K.K. Modulating TNF-a signaling with natural products. // Drug Discov Today.-2006.-V. 11 .-P.725−32.
129. Paunovic V., Carroll H.P., Vandenbroeck K., Gadina M. Signalling, inflammation and arthritis: Crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. //Rheumatology.-2008.-V.47.-P.771−6.
130. Pearson T.A. Coronary arteriography in the study of the epidemiology of coronary artery disease. //Epidemiol. Rev.-1984.-V.6.-P.140−66.
131. Pignoli P., Tremoli E., Poli A., Oreste P., Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. // Circulation.-1986.-V.74.-P.1399−1406.
132. Pinderski-Oslund L.J., Hedrick C.C., Olvera T., Hagenbaugh A., Territo M., Berliner J.A., Fyfe A.I. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. // ATVB.-1999.-V.19.-P.2847−53.
133. Pinkas J., Teicher B.A. TGF-b in cancer and as a therapeutic target. // Biochem Pharmacol.-2006.-V.72.-P.523−9.
134. Pletcher M.J., Tice J.A., Pignone M., Browner W.S. Using the coronaryartery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. // Arch. Intern.Med.-2004.-V.164.-P.1285−92.
135. Ranke C., Hecker H., Creutzig A., Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. //Circulation.-1993.-V.87.-P.1873−9.
136. Relton J.K., Rothwell N.J. Interleukin 1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. // Brain Research Bulletin.-1992.-V.29.-P.243−46.
137. Ridker P.M. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. // Eur Heart J.-1998.-V.19.-P.1−3.
138. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. // N Engl J Med.-1997.-V.336.-P.973−9.
139. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. // N Engl J Med.-2000.-V.342.-P.836−43.
140. Rodriguez-Yanez M., Castillo J. Role of inflammatory markers in brain ischemia. // Curr Opin Neurol.-2008.-V.21(3).-P.353−7.
141. Rosenbaum C.C., O’Mathuna D.P., Chavez M., Shields K. Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. // Altern Ther Health Med.-2010.-V.16(2).-P.32−40.
142. Rosenfeld M.E., Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparablyhypercholesterolemia fat-fed rabbits. // Arteriosclerosis.-1990.-V.10.-P.680−7.
143. Rosenfeld M.E., Yla-Herttuala S., Lipton B.A. et al. Macrophagecolony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. //Amer. J. Pathology.-1992.-V.140.-P.291−300.
144. Ross R. Atherosclerosis An Inflammatory Disease. Mechanisms of disease.-1999.-V.340.-P.115−26.
145. Rothwell N.J. Cytokines — killers in the brain? // Journal of Physiology.-1999.-V.514(l).-P.3−17.
146. Rus H., Niculescu F., Vlaicu R, Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. // Atherosclerosis.-1991.-V.89.-P.247−54.
147. Salonen J.T., Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. // Arterioscler Thromb.-1991.-V. 11.-P. 1245−9.
148. Salonen J.T., Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. // Circulation.-1993.-V.87.-P.56−65.
149. Salonen R, Salonen J.T. Progression of carotid atherosclerosis and its determinations: a population-based ultrasonography study. // Atherosclerosis.-1990.-V.81.-V.33−40.
150. Sawada M., Imamura K., Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. // J Neural Transm.-2006.-V.70.-P.373−81.
151. Schoenhagen P., Nissen S.E. Intravascular ultrasonography: using imaging end points in coronary atherosclerosis trials. Cleve. // Clin. J. Med.-2005.-V.72.-P.487−96.
152. Schonbeck U., Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? // Circulation.-2004.-V, 109.-P. 18−26.
153. Shah P.K. Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. // Circulation.-2000.-V.101.-P.1758−9.
154. Shimetani N. Evaluation of atherosclerosis using data on serum lipids, serum adiponectin, carotid ultrasonography, and pulse wave velocity: implications for preventive medical care. // Rinsho Byori.-2008.-V.56(10).-P.877−86.
155. Sidhu J.S., Kaposzta Z., Markus H.S., Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. // Arterioscler. Thromb. Vase. Biol.-2004.-V.24.-P.930−4.
156. Sipahi I., Nicholls S.J., Tuzcu E.M. Recent trends in coronary intravascular ultrasound: tracking atherosclerosis, pursuit of vulnerable plaques, and beyond. // J. Nucl. Cardiol.-2006.-V.13.-P.91−6.
157. Sitaraman S.V., Gewirtz A.T. Oprelvekin. Genetics Institute. // Curr Opin Investig Drugs.-2001 .-V.2.-P. 1395−1400.
158. Sobel R.A., Mitchell M.E., Fronden G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. // Am J Pathol.-1990.-V. 136.-P. 1309−16.
159. Sones F.M., Shirey E.K., Proudfrt W.L., Westcott R.N. Cinecoronary arteriography. // Circulation.-1959.-V.20.-P.773−4.
160. Somas R., Ostlund H., Muller R. Cerebrospinal fluid cytology afterstroke. // Arch Neurol.-1972.-V.26.-P.489−501.
161. Spelman K., Burns J., Nichols D., Winters N., Ottersberg S., Tenborg M. Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. // Altern Med Rev.-2006.-V.l 1.-P. 128−50.
162. Srivastava M.D., Srivastava B.I., Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. // Immunopharmacology.-1998.-V.40.-P. 179−85.
163. Stensland-Bugge, B0naa K.H., Joakimsen O. Age and sex differences in the relationship between inherited and lifestyle risk factors and subclinical carotid atherosclerosis: the Troms0 study. // Atherosclerosis.-2001.-V.154(2).-P.437−48.
164. Sukhova G.K., Williams J.K., Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. // ATVB, 2002- 22: 1452−1458.
165. Svenson M., Hansen M.B., Kayser L., Rasmussen A.K., Reimert C.M., Bendtzen K. Effects of human anti-IL-1 alpha autoantibodies on receptor binding and biological activities of IL-1. // Cytokine.-1992.-V.4.-P. 125−33.
166. Swiatecka-Urban A. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. // Paediatr Drugs.-2003V.5.-P.699−716.
167. Szczucinski A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. // Acta Neurol Scand.-2007.~V.115.-P. 137−46.
168. Tarkowski E. Cytokines in dementias. // Curr Drug Targets Inflamm Allergy .-2002.-V. 1 .-P.193−200.
169. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial
170. Terry J.G., Tang R., Espeland M.A., Davis D.H., Vieira J.C., Mercuri M.F., Crouse J.R. Carotid Arterial Structure in Patients With Documented Coronary Artery Disease and Disease-Free Control Subjects. // Circulation.-2002.-V.106.-P.2061.
171. Von der Thusen J.H., Kuiper J., Van Berkel T.J., Biesen E.A. Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential. // Pharmacol Rev.-2003.-V.55.-P. 133−66.
172. Tomimoto H., Akiguchi I., Wakita H., Kinoshita A., Ikemoto A., Nakamura S., Kimura J. Glial expression of cytokines in the brains of cerebrovascular disease patients. // Acta Neuropathol (Berl).1996.-V.92.-P.281−7.
173. Tuttolomondo A., Di Raimondo D., di Sciacca R., Pinto A., Licata G. Inflammatory cytokines in acute ischemic stroke. // Curr Pharm Des.-2008.-V.14(33).-P.3574−89.
174. Vidman T.R., Carpen O., Paetau A., Karjalainen-Lindsberg M.L., Lindsberg P.J. Production of tumor necrosis factor-a (TNF-a) in infarcted human brain. // Stroke.-1997.-V.28.-P.255.
175. Vincent J.L. Afelimomab. // Int J Clin Pract.-2000.-V.54.-P. 190−3.
176. Wang X., Siren A.L., Liu Y., Yue T.L., Barone F.C., Feuerstein G.Z. Upregulation of intercellular adhesion molecule 1 (ICAM-1) on brain microvascular endothelial cells in rat ischemic cortex. // Mol Brain Res.-1994.-V.26.-P.61−8.
177. Whicher J.T., Evans S.W. Cytokines in disease. // Clin. Chem.-1990.-V.36.-P. 1269−81.
178. Witkowska-Banaszczak E., Bylka W., Matlawska I., Goslinska O., Muszynski Z. Antimicrobial activity of Viola tricolor herb. // Fitoterapia.-2005.-V.76(5).-P. 458−61.
179. Wittig B.M. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. // Curr Opin Investig Drugs.-2007.-V.8.-P.947−54.
180. Woods A., Brull D.J., Humphries S.E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. // Eur. Heart J.-2000.-V.21 .-P. 1574−83.
181. Yesilada E., Ustun O., Sezik E., Takaishi Y., Ono Y., Honda G. Inhibitory effects of Turkish folk remedies on inflammatory cytokines: interleukin-1 alpha, interleukin-lbeta and tumor necrosis factor alpha. // J Ethnopharmacol.-1997.-V.58.-P.59−73.
182. Yock P.G., Johnson E.L., Linker D.T. Intravascular ultrasound: development and clinical potential. // Am. J. Card. Imaging.-1988.-V.2.-P. 185−93.
183. Yoshizumi M., Perrella M.A., Burnett J.CJr., Lee M.E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. // Circ. Res.-1993.-V.73.-P.205−9.
184. Zanchetti A. Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. // Clin Exp Hypertens.-1996.-V.18(3−4)-P.489−99.